GlassScriptPhysician profile
Michael John Coffey
NPI 1225091564
$3,620.00
in general payments reported to CMS, 2019-2025
21 companies · $526 in 2025
The $526 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $397 · 2020: $185 · 2021: $611 · 2022: $710 · 2023: $481 · 2024: $711 · 2025: $526.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,634 · Education: $84.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,633.75 |
| Education | $84.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,476.28 | 2019-2025 | Rinvoq, Mavyret, Skyrizi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $670.18 | 2019-2024 | Xifaxan |
| Janssen Biotech, INC. | $302.15 | 2019-2024 | Stelara, Tremfya |
| Celgene Corporation | $186.85 | 2021-2024 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $181.51 | 2019-2025 | Entyvio |
| Pfizer INC. | $143.08 | 2019-2025 | |
| Braintree Laboratories, INC. | $122.48 | 2019-2024 | Suflave, Sutab |
| Lilly USA, LLC | $76.88 | 2024-2025 | Omvoh |
| Aimmune Therapeutics, INC. | $69.22 | 2025 | Zenpep |
| Ardelyx, INC. | $64.89 | 2024-2025 | Ibsrela |
| Redhill Biopharma INC. | $63.15 | 2020-2022 | |
| Novo Nordisk INC | $46.05 | 2025 | Wegovy |
| Madrigal Pharmaceuticals | $45.01 | 2025 | Rezdiffra |
| Phathom Pharmaceuticals, INC. | $38.02 | 2024-2025 | Voquezna |
| Ferring Pharmaceuticals INC. | $31.24 | 2019-2023 | Rebyota |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $20.06 | 2025 | Pillcam |
| Nestle Healthcare Nutrition INC. | $19.81 | 2023 | |
| Intercept Pharmaceuticals, INC. | $19.07 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $17.19 | 2022 | |
| Echosens North America, INC. | $15.32 | 2024 | Fibroscan |
| Ironwood Pharmaceuticals, INC | $11.56 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Coffey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.